Gender-affirming hormone therapy also affected by ‘myths of E and P’

+Practice
In print
Sexual health

Gender-affirming hormone therapy also affected by ‘myths of E and P’

By Massimo Giola
P E
Oestrogen-based gender-affirming hormone therapy has the additional challenge of myths concerning progestogen [Image: Carl Hunley Jr on Unsplash]

Sexual health specialist Massimo Giola discusses some common misunderstandings about the use of oestrogen and progestogen in transfeminine gender-diverse people

Key points, The gender-diverse community is very connected at an international level. Some myths about hormone therapy have been going around for a long time. , Pract Green w Pale Yellow
References

1. Nolan BJ, Frydman AS, Leemaqz SY, et al. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocr Connect 2022;11(5):e220170.

2. Sudhakar D, Huang Z, Zietkowski M, et al. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks. Neurourol Urodyn 2023;42(5):903–20.

3. Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 2022;23(Suppl 1):S1–259.